EMA

Does anyone understand the statement stated in the EMA Agenda?

"
(EMEA/H/D/002831), ((substance to be reviewed) insulin-like growth factor-i (igf-i) segment), (hard-to-heal wounds, primarily venous leg ulcers) List of Questions adopted on 23.01.2014. • List of Outstanding Issues: For adoption
"

I believe that means only that the outstanding issues will be discussed at the meeting and is for adoption by the Commitee.